Open | $22.250 |
Close | $22.100 |
Volume / Avg. | 335.551K / 674.098K |
Day Range | 21.815 - 22.940 |
52 Wk Range | 4.440 - 30.958 |
Market Cap | $1.241B |
P/E Ratio | - |
Dividend Yield | - |
Exchange | NASDAQ |
RSI | 45 |
Short Interest | 6.92% |
Days to Cover | 3.35 |
Name |
---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
You can purchase shares of Immunome (NASDAQ: IMNM) through any online brokerage.
Other companies in Immunome’s space includes: 89bio (NASDAQ:ETNB), Gyre Therapeutics (NASDAQ:GYRE), 4D Molecular Therapeutics (NASDAQ:FDMT), Prothena Corp (NASDAQ:PRTA) and Immatics (NASDAQ:IMTX).
The latest price target for Immunome (NASDAQ: IMNM) was reported by Wedbush on Tuesday, January 23, 2024. The analyst firm set a price target for 19.00 expecting IMNM to fall to within 12 months (a possible -12.44% downside). 3 analyst firms have reported ratings in the last year.
The stock price for Immunome (NASDAQ: IMNM) is $21.7 last updated March 18, 2024 at 7:55 PM EDT.
There are no upcoming dividends for Immunome.
Immunome’s Q1 earnings are confirmed for Friday, May 3, 2024.
There is no upcoming split for Immunome.
Immunome is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.